Related Experiment Video

Updated: Dec 8, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Sergey Karakashev1, Rugang Zhang1

  • 1Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.

Molecular & Cellular Oncology
|September 18, 2020
PubMed

Insights

High-grade serous ovarian cancers expressing CARM1 have poor outcomes. A new strategy combines PARP and EZH2 inhibitors to target these aggressive cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • High-grade serous ovarian cancer (HGSOC) often presents with aggressive disease and limited treatment efficacy.
  • Coactivator-associated arginine methyltransferase 1 (CARM1) expression is linked to poor prognosis in HGSOC.
  • Current therapeutic options for CARM1-expressing HGSOC are insufficient.

Purpose of the Study:

  • To propose a novel therapeutic strategy for CARM1-expressing ovarian cancer.
  • To investigate the potential of combining poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

Main Methods:

  • This study discusses a therapeutic strategy.
  • The strategy involves the combined inhibition of PARP and EZH2.

Main Results:

  • The proposed combination therapy targets CARM1-expressing ovarian cancers.
  • This approach offers a novel therapeutic avenue for a challenging cancer subtype.

Conclusions:

  • Targeting CARM1-expressing HGSOC with a combination of PARP and EZH2 inhibitors is a promising strategy.
  • This novel approach may improve outcomes for patients with poor-prognosis ovarian cancer.
Keywords:
coactivator-associated arginine methyltransferase 1 (CARM1)enhancer of zeste homology 2 (EZH2) inhibitorsepithelial ovarian cancerhomologous recombination (HR)immune checkpoint blockersmitotic arrest deficient 2 like 2 (MAD2L2)non-homologous end-joining (NHEJ)poly (ADP-ribose) polymerase (PARP) inhibitors

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

568
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K